the Biotech JV is not expected to generate revenues for years, due to completion of clinical trials which take years sometimes
Some bank loans are based on future revnues. The backing by Wahana and a possible revenue source from JV could be enough to push the loan through. Clearly, there has been some hesitation from the banks up to this point. Of course, it all depends on if they get the loan.
the Biotech JV is not expected to generate revenues for years, due to completion of clinical trials which take years sometimes
Some bank loans are based on future revnues. The backing by Wahana and a possible revenue source from JV could be enough to push the loan through. Clearly, there has been some hesitation from the banks up to this point. Of course, it all depends on if they get the loan.